ArticleBMC infectious diseases2026
Impacts of relaxed mask policies on COVID-19 epidemics: a modeling study in South Korea.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe COVID-19 pandemic led to widespread use of non-pharmaceutical interventions (NPIs), including mask mandates. Although many studies have examined COVID-19 policies, there is a lack of research on the impact of mask mandate relaxation in South Korea. Retrospective analyses of this topic are essential to inform optimized policy responses in future pandemics.
methodsWe used a discrete-time, age-structured Susceptible-Exposed-Infectious-Vaccinated-Recovered (SEIVR) compartmental model to simulate COVID-19 transmission in South Korea and conducted counterfactual analyses to assess the impact of five major mask policy adjustment points (PAPs). The model estimated changes in confirmed cases, severe cases, and deaths under counterfactual scenarios in which mask mandates were relaxed 2 weeks earlier or later than they were in reality. Analyses were stratified by age group to evaluate differential effects.
resultsChanges in Rt (effective reproduction number) following mask policy relaxations were modest across all five PAPs. While some policy shifts were followed by slight increases or decreases in Rt, none led to uncontrolled epidemic growth. Counterfactual simulations showed that advancing mask relaxation by 2 weeks could have led to significantly more confirmed cases, with increases of up to 29.5% in the 0-17 years group and 25.2% in the ≥ 60 years group, compared to the observed timeline. Conversely, delaying relaxation reduced case numbers across all age groups. The timing of relaxation, especially when Rt was low, appeared to play a more critical role than population immunity in determining transmission outcomes. A positive association was observed between higher Rt at the time of relaxation and increased case counts, whereas immunity levels did not show a consistent correlation.
conclusionsThe timing of mask mandate relaxation substantially influenced short-term COVID-19 transmission dynamics. Real-time indicators such as Rt were more predictive of outcomes than estimated immunity levels, suggesting their utility for informing policy adjustments. Counterfactual evidence indicates that premature relaxation increased cases across all age groups, with age differences more evident at certain adjustment points. The public health implications remain greater for vulnerable populations because even similar percentage increases translate into higher absolute risks. Policymakers should incorporate transmission dynamics, age-specific vulnerability profiles, and timing considerations into future pandemic response strategies. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.